Heart Disease
Zhittya Genesis Medicine is developing FGF-1 to treat Coronary Artery Disease (CAD) by growing new blood vessels around blockages in the heart. Thereby, increasing blood supply and extending the life expectancy of patients by years and even decades, while also reducing pain and increasing quality of life.
Over 80 patients with CAD have been dosed with FGF-1 in three different clinical trials in the United States and Germany over the last 20 years. All patients showed great improvement, with no adverse events reported attributable to FGF-1 in the studies. The successful results of these studies were posted in Circulation, the American Heart Association’s peer-reviewed academic journal.
Zhittya plans to restart its research into Coronary Artery Disease in both clinical trials and medical research studies for the public.
Our Data: Pictured and Graphed
Watch as Zhittya Genesis Medicine’s drug is used to grow new blood vessels in the human heart in a US FDA Phase I Clinical Trial done at the University of Cincinnati, and reported by ABC Nightly News.
In a US FDA Phase I Clinical Trial, FGF-1 was able to grow around blocked arteries in the heart. By growing around these blocked arteries, FGF-1 was able to treat coronary artery disease, allowing for these patients to reduce chest pain and begin to return to normal. The plush shown on the right side indicates new blood vessels growing around blocked arteries in the heart.
History
The first coronary artery disease trial in humans with FGF-1 was performed in Germany at the Fulda Medical Center in Fulda, Germany. 40 patients were in the study and 20 patients had received the FGF-1.
In all 20 patients that received FGF-1, a blush of new blood vessels could be observed on angiograms. Blood vessel density increased by three times and remained three years after the treatment, supplying blood and nutrients to the heart.
A second trial in Germany would follow, focusing on both safety and efficacy of the drug. The conclusion of the study indicated that not only was the drug safe, showing no adverse events; but that patients had improved in heart pain, heart stress, and exercise scoring.
After these successful trials, the technology would be transferred to the United States to conduct a US FDA Phase I Clinical Trial in partnership with the University of Cincinatti. 21 patients would be recruited for this trial, resulting in statistical improvements after only 12 weeks. The results were so impressive that American Broadcasting Channel (ABC) would go onto make a report about it.
Watch Zhittya’s full presentation discussing how FGF-1 could be used to treat Coronary Artery Disease by growing new blood vessels around blocked arteries in the heart. A process which has demonstrated to be effective in three clinical trials in Europe and the United States.